CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Metrics to compare | 2616 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2616PeersSector | |
---|---|---|---|---|
P/E Ratio | −27.5x | −14.0x | −0.5x | |
PEG Ratio | −0.35 | −0.17 | 0.00 | |
Price/Book | 8.4x | 4.1x | 2.6x | |
Price / LTM Sales | 8.6x | 12.6x | 3.0x | |
Upside (Analyst Target) | 34.8% | 28.1% | 55.6% | |
Fair Value Upside | Unlock | 10.1% | 10.1% | Unlock |